Replies to post #313077 on $Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

A TEN SHUN>7:15 AM Following its fraud charge against Goldman (GS), the SEC is investigating whether other Wall Street firms misled investors over mortgage investments. But while the SEC can brag that it's sending a warning to Wall Street, it's also putting its own reputation on the line.

[Tuff-Stuff]

HGSI<<<going down-Bounce ?

[Tuff-Stuff]

reply> Human Genome Sciences Runs Into Lupus Concern

(HGSI)
Posted in pre-market on April 20th, 2010
Comments Off

Human Genome Sciences Inc. (NASDAQ: HGSI) is trading lower after it and GlaxoSmithKline (NYSE: GSK) announced topline 76-week results of the Phase III BLISS-76 trial of Benlysta in Systemic Lupus Erythematosus… BENLYSTA already met its primary efficacy endpoint at Week 52 in both BLISS-52 and BLISS-76 studies in July and November 2009; at Week 76 in the BLISS-76 study, belimumab plus standard of care showed higher response rates….; BUT… this secondary endpoint did not reach statistical significance. Belimumab continued to be generally well tolerated with overall adverse event rates comparable between belimumab and placebo treatment groups.

HGSI shares are lower on the secondary endpoint not being met. At 8:17 AM EST we have shares trading down about 5.5% at $29.75 on over 300,000 shares.

Please note, there may be some study leakage here. Yesterday the stock was down almost $1.00 to $31.49 after being at $32.42 Friday and yesterday’s 4.054 million shares was the most active day since April 7. The problem is that its partner NOVARTIS yesterday withdrew JOULFERON new drug application with the European Medicines Agency to treat hepatitis C.

Stay tuned.

JON OGG

[Tuff-Stuff]

reply HGSI going dwwwwwwwwwwn!